TGF-β1 induces HMGA1 expression in human breast cancer cells: Implications of the involvement of HMGA1 in TGF-β signaling

International Journal of Molecular Medicine

Volumn 35, Issue 3, 2015, Pages 693-701

  Zu, Xuyu ^a   Zhong, Jing ^a   Tan, Jingjing ^a   Tan, Li ^a   Yang, Dong ^a   Zhang, Qinghai ^a   Ding, Wenjun ^a   Liu, Wen ^a   Wen, Gebo ^a   Liu, Jianghua ^a   Cao, Renxian ^a   Jiang, Yuyang ^b  

^a THE FIRST AFFILIATED HOSPITAL OF UNIVERSITY OF SOUTH CHINA   (China)

^b TSINGHUA UNIVERSITY   (China)

Author keywords

Breast cancer; High mobility group A1; Human epidermal growth factor receptor 2; Transforming growth factor 1

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HIGH MOBILITY GROUP A1A PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR SP1; TRANSFORMING GROWTH FACTOR BETA1; WORTMANNIN; HIGH MOBILITY GROUP A PROTEIN;

ARTICLE; BINDING AFFINITY; BREAST CANCER CELL LINE; BREAST CARCINOMA; CANCER GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOFLUORESCENCE TEST; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION; ADULT; AGED; BREAST TUMOR; CANCER GRADING; CANCER STAGING; CELL MOTION; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; TRANSCRIPTION INITIATION; TUMOR CELL LINE; TUMOR VOLUME;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGA PROTEINS; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION; TRANSFORMING GROWTH FACTOR BETA1; TUMOR BURDEN;

EID: 84921742843     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2015.2062     Document Type: Article

References (34)

1. Porter PL: Global trends in breast cancer incidence and mortality. Salud Publica Mex 51 (Suppl 2): s141-s146, 2009.
2. Yang L, Pang Y and Moses HL: TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 31: 220-227, 2010.
3. Smith AL, Robin TP and Ford HL: Molecular pathways: targeting the TGF-β pathway for cancer therapy. Clin Cancer Res 18: 4514-4521, 2012.
4. Derynck R, Akhurst RJ and Balmain A: TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129, 2001.
5. Reeves R: Nuclear functions of the HMG proteins. Biochim Biophys Acta 1799: 3-14, 2010.
6. Resar LM: The high mobility group A1 gene: transforming inflammatory signals into cancer? Cancer Res 70: 436-439, 2010.
7. Fusco A and Fedele M: Roles of HMGA proteins in cancer. Nat Rev Cancer 7: 899-910, 2007.
8. Ben-Porath I, Thomson MW, Carey VJ, et al: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499-507, 2008.
9. Chou BK, Mali P, Huang X, et al: Efficient human iPS cell derivation by a non-integrating plasmid from blood cells with unique epigenetic and gene expression signatures. Cell Res 21: 518-529, 2011.
10. Karp JE, Smith BD, Resar LS, et al: Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood 117: 3302-3310, 2011.
11. Nelson DM, Joseph B, Hillion J, Segal J, Karp JE and Resar LM: Flavopiridol induces BCL-2 expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemia. Leuk Lymphoma 52: 1999-2006, 2011.
12. Schuldenfrei A, Belton A, Kowalski J, et al: HMGA1 drives stem cell, inflammatory pathway, and cell cycle progression genes during lymphoid tumorigenesis. BMC Genomics 12: 549, 2011.
13. Belton A, Gabrovsky A, Bae YK, et al: HMGA1 induces intestinal polyposis in transgenic mice and drives tumor progression and stem cell properties in colon cancer cells. PLoS One 7: e30034, 2012.
14. Shah SN and Resar LM: High mobility group A1 and cancer: potential biomarker and therapeutic target. Histol Histopathol 27: 567-579, 2012.
15. Abe N, Watanabe T, Masaki T, et al: Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res 60: 3117-3122, 2000.
16. Chiappetta G, Tallini G, De Biasio MC, et al: Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 58: 4193-4198, 1998.
17. Chiappetta G, Manfioletti G, Pentimalli F, et al: High mobility group HMGI(Y) protein expression in human colorectal hyperplastic and neoplastic diseases. Int J Cancer 91: 147-151, 2001.
18. Chiappetta G, Botti G, Monaco M, et al: HMGA1 protein overexpression in human breast carcinomas: correlation with ErbB2 expression. Clin Cancer Res 10: 7637-7644, 2004.
19. Meyer B, Loeschke S, Schultze A, et al: HMGA2 over-expression in non-small cell lung cancer. Mol Carcinog 46: 503-511, 2007.
20. Masciullo V, Baldassarre G, Pentimalli F, et al: HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas. Carcinogenesis 24: 1191-1198, 2003.
21. Tamimi Y, van der Poel HG, Denyn MM, et al: Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res 53: 5512-5516, 1993.
22. Miyazawa J, Mitoro A, Kawashiri S, Chada KK and Imai K: Expression of mesenchyme-specific gene HMGA2 in squamous cell carcinomas of the oral cavity. Cancer Res 64: 2024-2029, 2004.
23. Rho YS, Lim YC, Park IS, et al: High mobility group HMGI(Y) protein expression in head and neck squamous cell carcinoma. Acta Otolaryngol 127: 76-81, 2007.
24. Dolde CE, Mukherjee M, Cho C and Resar LM: HMG-I/Y in human breast cancer cell lines. Breast Cancer Res Treat 71: 181-191, 2002.
25. Zhong J, Cao RX, Zu XY, et al: Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma. FEBS J 279: 316-335, 2012.
26. Welch DR, Fabra A and Nakajima M: Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87: 7678-7682, 1990.
27. Derynck R and Zhang YE: Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 425: 577-584, 2003.
28. Moustakas A and Heldin CH: Non-Smad TGF-β signals. J. Cell Sci 118: 3573-3584, 2005.
29. Massimi I, Guerrieri F, Petroni M, Veschi V, Truffa S, Screpanti I, Frati L, Levrero M, Gulino A and Giannini G: The HMGA1 protoncogene frequently deregulated in cancer is a transcriptional target of E2F1. Mol Carcinog 52: 526-534, 2013.
30. Abe N, Watanabe T, Izumisato Y, et al: High mobility group A1 is expressed in metastatic adenocarcinoma to the liver and intrahepatic cholangiocarcinoma, but not in hepatocellular carcinoma: its potential use in the diagnosis of liver neoplasms. J Gastroenterol 38: 1144-1149, 2003.
31. Shah SN, Kerr C, Cope L, et al: HMGA1 reprograms somatic cells into pluripotent stem cells by inducing stem cell transcriptional networks. PLoS One 7: e48533, 2012.
32. Wang Q, Ji Y, Wang X and Evers BM: Isolation and molecular characterization of the 5'-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 276: 466-471, 2000.
33. Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA and Kavurma MM: TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phos-phorylation-, and NF kappa B-dependent manner. Circ Res 106: 1061-1071, 2010.
34. Flohr AM, Rogalla P, Bonk U, et al: High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol 18: 999-1004, 2003.